In the newly established initiative, the Neuro-CERVO Alliance for Drug Discovery (NCADD) is welcoming a new Montreal-based private partner, Simmunome, to untangle biological pathways and identify biomarkers involved in neurological and psychiatric disorders. Simmunome’s expertise in simulating disease states will be an invaluable asset to shed light onto potential therapeutic targets for these devastating conditions.

We are thrilled to partner with Front Row Ventures to continue driving innovation in the areas of oncology, neurodegenerative diseases and regenerative medicine.

“Being recognized for our work in AI is not only honoured recognition, it validates the importance of the work we do for clinical research,” says Co-Founder and CTO Nardin Nakhla.